Complix NV, a biopharmaceutical company focused on the discovery and development of Alphabodies™, a novel class of protein therapeutics, announced today that it has progressed its first Alphabody™ product, CMPX-1023, into preclinical development. CMPX-1023 is under development for treatment of autoimmune diseases and inflammation. Complix has achieved this important milestone less than 12 months after starting the discovery program for this compound, illustrating the efficiency of its proprietary Alphabody™ discovery engine. CMPX-1023 is Complix´s first Alphabody™ entering the development phase. Complix has other ongoing discovery programs for Alphabody™ therapeutics against autoimmune and viral diseases.

CMPX-1023 is a novel therapeutic Alphabody™ that binds with high affinity and selectivity to a key functional epitope of an undisclosed autoimmune disease target. In preclinical models CMPX-1023 has demonstrated impressive potency and selectivity. Given these promising results, CMPX-1023 has the potential to become a valuable therapeutic for treatment of autoimmune disorders, with a superior safety profile as compared to currently marketed drugs. CMPX-1023 was selected from a panel of more than 20 potent antagonists obtained in this program against the defined target.
Complix anticipates to file an Investigational New Drug (IND) application for CMPX-1023 in the first half of 2013.
Dr. Mark Vaeck, CEO of Complix, commented: “We are extremely pleased with the speed at which our first therapeutic Alphabody™ product candidate reached the development stage. It is a clear endorsement of the power of our discovery engine that enables to rapidly generate multiple promising leads against important disease targets.”
 

The Alphabody™ discovery platform applies rational design to generate optimized lead compounds with unrivalled binding affinity to preselected epitopes of functionally important disease targets. Often such crucial target epitopes are difficult or impossible to address with conventional antibody technology or other drug screening platforms.
 

Contacts
Complix NV
Dr. Mark Vaeck, CEO
T: +32 9 261 69 40
E: mark.vaeck@complix.com